NCT01022736View on ClinicalTrials.gov

Plasma Gabapentin Concentration During and Following Cardiac Bypass

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Cardiopulmonary Bypass
Interventions
DRUG

Gabapentin

Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.

Trial Locations (1)

K 7L 2V7

Kingston General Hospital, Kingston

All Listed Sponsors
lead

Queen's University

OTHER

NCT01022736 - Plasma Gabapentin Concentration During and Following Cardiac Bypass | Biotech Hunter | Biotech Hunter